Literature DB >> 22391769

The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia.

S A Lott1, P R Burghardt, K J Burghardt, M J Bly, T B Grove, V L Ellingrod.   

Abstract

The catechol-O-methyl transferase (COMT) 158Val/Met variant has been suggested to play a role in COMT function. Epigenetic regulation of COMT may further influence the prevalence of metabolic syndrome in these patient populations. This study examined the correlation between COMT promoter methylation and metabolic syndrome in schizophrenia patients receiving atypical antipsychotic (AAP) therapy. DNA was extracted from peripheral blood samples of schizophrenia subjects screened for metabolic syndrome. Pyrosequencing was used to analyze two methylation sites of the soluble COMT (COMT-s) promoter region. Associations between AAP use, lifestyle variables, metabolic syndrome and COMT genotype with peak methylation values were analyzed. Data are reported in 85 subjects. Methylation on CpG site 1 had a mean of 79.08% (±4.71) and it was 12.43% (±1.19) on site 2. COMT genotype proved to be an indicator of COMT methylation status on site 1 (F(2, 84)=5.78, P=0.0044) and site 2 (F(2, 84),=3.79, P=0.027). A significant negative correlation between physical activity and COMT promoter region methylation was found in Val/Val homozygous patients (site 1: P=0.013 and site 2: P=0.019). Those homozygous for Met/Met showed a positive correlation between promoter site methylation and physical activity (site 1: P=0.027, site 2: P=0.005), and between CpG site methylation and metabolic syndrome (site 1: P=0.002; site 2: P=0.001). The results of this study suggest that COMT promoter region methylation is largely influenced by COMT genotype and that physical activity plays a significant role in epigenetic modulation of COMT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391769      PMCID: PMC3663896          DOI: 10.1038/tpj.2012.6

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  31 in total

Review 1.  Incidental neurodevelopmental episodes in the etiology of schizophrenia: an expanded model involving epigenetics and development.

Authors:  S M Singh; P McDonald; B Murphy; R O'Reilly
Journal:  Clin Genet       Date:  2004-06       Impact factor: 4.438

2.  Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.

Authors:  Hamid Mostafavi Abdolmaleky; Kuang-Hung Cheng; Stephen V Faraone; Marsha Wilcox; Stephen J Glatt; Fangming Gao; Cassandra L Smith; Rahim Shafa; Batol Aeali; Julie Carnevale; Hongjie Pan; Panagiotis Papageorgis; Jose F Ponte; Vadivelu Sivaraman; Ming T Tsuang; Sam Thiagalingam
Journal:  Hum Mol Genet       Date:  2006-09-19       Impact factor: 6.150

Review 3.  The catechol-O-methyltransferase gene: its regulation and polymorphisms.

Authors:  Elizabeth M Tunbridge
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

4.  Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms.

Authors:  S Dawling; N Roodi; R L Mernaugh; X Wang; F F Parl
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

5.  MTHFR and risk of metabolic syndrome in patients with schizophrenia.

Authors:  Ruud van Winkel; Bart P Rutten; Odette Peerbooms; Joseph Peuskens; Jim van Os; Marc De Hert
Journal:  Schizophr Res       Date:  2010-06-12       Impact factor: 4.939

6.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

7.  Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

Authors:  Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr
Journal:  Schizophr Res       Date:  2007-10-31       Impact factor: 4.939

Review 8.  The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes.

Authors:  Robert M Bilder; Jan Volavka; Herbert M Lachman; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2004-11       Impact factor: 7.853

Review 9.  Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome?

Authors:  Hanno Pijl
Journal:  Eur J Pharmacol       Date:  2003-11-07       Impact factor: 4.432

10.  Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels.

Authors:  Elizabeth M Tunbridge; Paul J Harrison; Donald R Warden; Carole Johnston; Helga Refsum; A David Smith
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

View more
  19 in total

1.  Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults.

Authors:  Karolina A Aberg; Joseph L McClay; Srilaxmi Nerella; Shaunna Clark; Gaurav Kumar; Wenan Chen; Amit N Khachane; Linying Xie; Alexandra Hudson; Guimin Gao; Aki Harada; Christina M Hultman; Patrick F Sullivan; Patrik K E Magnusson; Edwin J C G van den Oord
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

Review 2.  Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future.

Authors:  Emma Dempster; Joana Viana; Ruth Pidsley; Jonathan Mill
Journal:  Schizophr Bull       Date:  2012-12-04       Impact factor: 9.306

3.  Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.

Authors:  Yi Zhang; Meijuan Chen; Jun Chen; Zhiguo Wu; Shunying Yu; Yiru Fang; Chen Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-01-22       Impact factor: 4.530

4.  Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children.

Authors:  A T Cote; C Panagiotopoulos; A M Devlin
Journal:  Pharmacogenomics J       Date:  2014-07-22       Impact factor: 3.550

5.  DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder.

Authors:  Kyle J Burghardt; Jacyln M Goodrich; Dana C Dolinoy; Vicki L Ellingrod
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

6.  Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review.

Authors:  Kyle J Burghardt; Audrey S Khoury; Zaher Msallaty; Zhengping Yi; Berhane Seyoum
Journal:  Pharmacotherapy       Date:  2020-03-09       Impact factor: 4.705

Review 7.  Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed.

Authors:  Tahireh A Shams; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

Review 8.  Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?

Authors:  Kyle J Burghardt; Vicki L Ellingrod
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

9.  Analysis of COMT Val158Met polymorphisms and methylation in Chinese male schizophrenia patients with homicidal behavior.

Authors:  Yikai Hu; Chenghu Li; Yangfan Wang; Qinhan Li; Yidong Liu; Shengde Liao; Peiqing Cao; Hongmei Xu
Journal:  Int J Legal Med       Date:  2018-02-17       Impact factor: 2.686

Review 10.  Epigenetic mechanisms in the development of behavior: advances, challenges, and future promises of a new field.

Authors:  Tania L Roth
Journal:  Dev Psychopathol       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.